Stories - Part 2

Download PDF

Register to download the report. Already a member?

Sign Up


67053 1513184208HCLSReviewBulgariaDecember2017.pdf
Energy Boardroom

Pharma Stories & Articles


Tunisia: A New Framework for Biotech Investments

The long-awaited conference marking the launch of the company cluster of Sidi Thabet (a city in the governorate of Ariana, 20 minutes from Tunis airport) took place on September 28th 2017 at the Tunis export centre (CEPEX) and revolved around …


Austria: Nucleus of Clinical Trials

Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia, willing volunteers and educated medical personnel balanced against a backdrop …


Austria: Orchestrating Innovation

Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing as Austria capitalizes on its ideal central European location and …


Euratom: Where Are We Now?

Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving the European Atomic Energy Community (Euratom) on cancer care in …


Hong Kong: A Clinical Trials Destination

Small markets must inevitably etch out a niche positioning for themselves, and for Hong Kong, its world-class medical infrastructure, world-renowned academics and clinicians as well as high population density make it a strong contender in clinical research. “Hong Kong is …


Hong Kong: Land of the Biotech Unicorns

In 2017, Hong Kong fended off perennial competitors, life sciences hubs and innovation powerhouses, Switzerland and Singapore, to rank first in the International Institute for Management Development (IMD)’s World Competitiveness Rankings, clear evidence that conditions are ripe in Hong Kong …


The Indonesian Halal Law: A Headache for Pharma

The Halal Product Assurance Law, enacted in 2014 and due to be implemented across Indonesia in 2019, will mandate that all food and drink that that enters, is distributed, and is traded in Indonesia must be halal certified. However, the …


Countering NCDs in Algeria

Long considered maladies of affluent urban populations in mature Western economies, non communicable diseases (NCDs)– such as diabetes, cancer, chronic respiratory and cardiovascular diseases – have been spreading silently and unchecked throughout the African continent to the point where they …


Expanscience Mexico along with its key brand Mustela reveals the physiology of babies’ skin via a 10 year research called E.V.E.I.L.S.

More about Laboratoire Expanscience Mexico : More about Mustela Mexico :


Sources of Disruption in Today’s Pharma Industry

PharmaBoardroom’s readers were polled on what they felt was the most disruptive force in the pharmaceutical industry today. Possible answers were big data and digitalization, patient-centricity, economic austerity, and advancements in supply chain management. Big Data and Digitalization Overall, most …


Round Table Discussion on Algerian Public Healthcare Provision

In June 2017, PharmaBoardroom hosted an exclusive round table discussion with key players in Algerian healthcare on the role of health economics and patient data in health policy decision making. The participants were Dr Djaouad Brahim Bourkaib, Director General of Social …


FDA New Drug Approvals 2017

In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The …




Most Read

Download PDF

First Name:

Last Name: